When we compared IL-2-activated CD52+ NK cells and CD52− NK cells, we found that CD52− NK cells exhibited 4-fold greater cytotoxicity against K562 tumor cells compared with CD52+ NK cells (Fig 4B). The gene discussed is CD52; the disease is neoplasm.